Whalesbook
Buyback ki khabar se stock mein toofani tezi!
Arre bhai, Aurobindo Pharma ka share aaj market mein raja bankar nikla! Wednesday, April 1, 2026 ko, yeh stock seedha National Stock Exchange par 52-week high, yaani ₹1,355.50 ke level par pahunch gaya. Iska sabse bada reason hai company ke Board of Directors ki meeting jo April 6, 2026 ko hone wali hai, jisme share buyback proposal par विचार (thought/consideration) kiya jayega. Is khabar ne stock mein ekdum se tezi la di. Saath hi, is saal ab tak stock ne 14% ka return diya hai, jabki Nifty 50 toh same period mein 11% gir gaya hai! Pichhle ek mahine mein bhi Aurobindo Pharma 11% upar gaya hai, wahi Nifty 50 7.8% neeche gira. Yaad hoga, mid-2024 mein bhi company ne ₹750 crore ka buyback complete kiya tha.
Growth strategy aur kam valuation ka fayda!
Company apne business ko jyada profit wale segments mein expand kar rahi hai, jahan se Return on Invested Capital (RoIC) acha milta hai. JM Financial Institutional Securities ke analysts ka kehna hai ki agle do saal mein RoIC lagbhag 470 basis points badh sakta hai. Isme Pen-G, biosimilars, Merck ke saath biologics deal, Lannett acquisition, aur Adquey launch jaise cheezein shamil hain. Agar projections sahi nikli, toh FY26 se FY28 ke beech revenue mein 17%, EBITDA mein 21%, aur PAT (Profit After Tax) mein 26% ka compound annual growth rate (CAGR) dekhne ko mil sakta hai. Abhi valuation ki baat karein toh, FY28 ke earnings per share (EPS) par stock lagbhag 13x P/E par trade kar raha hai, jabki competitors ka average 23x ke aas-paas hai. March 2026 tak trailing twelve-month (TTM) P/E ratio 21.5x ke aas-paas tha. Sun Pharmaceutical Industries (38.33x), Divi's Laboratories (62.68x), aur Torrent Pharmaceuticals (62.62x) jaise bade players ke comparison mein yeh kafi attractive hai. Haan, Dr. Reddy's Laboratories (19.01x) ke aas-paas hai. March 2026 mein company ki market capitalization lagbhag ₹75,690 crore thi.
Regulatory hurdles par bhi nazar rakhni hogi
Waise toh sab theek lag raha hai, par company ko USFDA (U.S. Food and Drug Administration) se related kuch challenges face karne pad rahe hain. Early 2026 mein, unki Unit-7 facility mein data integrity, equipment cleaning, aur computer system controls ko lekar critical observations mili thi. Ek microbiologist par data falsify karne ke allegations bhi lage the. Isse import bans, product recalls, ya approvals delay hone ka risk rehta hai, jo unke vital U.S. generics business ko affect kar sakta hai, jahan Q3 mein sirf 2% revenue growth tha. Management ne inko procedural bataya tha, par market pehle bhi aise issues par negatively react kar chuka hai. Pichhle saal Aceto Corporation ne bhi 2019 mein supply chain control ko lekar fraud aur breach of contract ke allegations lagaye the. Sector mein Sun Pharma aur Cipla jaise bade naam bhi regulatory issues se guzre hain. Achhi baat yeh hai ki Non-Executive Director P. Sarath Chandra Reddy ko Delhi Liquor Policy case se February 2026 mein discharge kar diya gaya tha.
Analysts kya keh rahe hain?
Analysts Aurobindo Pharma ke future ko lekar kaafi optimistic hain. JM Financial ne BUY rating ke saath ₹1,610 ka target diya hai, aur upcoming fiscal years ke liye strong growth projections hain. Technical analysts ko bhi stock mein bullish trend dikh raha hai, jahan stock breakout de raha hai aur important moving averages se upar trade kar raha hai. Woh ₹1,308 ke aas-paas buy karke ₹1,517 ka target rakhne ki salah de rahe hain. Overal Indian pharma sector FY26 mein 7-9% grow hone ka estimate hai, par input costs badhne aur US market mein pricing pressure jaisi challenges bhi hain.